Gut microbiota–cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation

Basit Öğe Kaydı
dc.contributor.authorAbavisani, Mohammad Amin
dc.contributor.authorSajjadi, Seyed Mohammad
dc.contributor.authorEbadpour, Negar
dc.contributor.authorKarav, Sercan
dc.contributor.authorSahebkar, Amirhossein Hosein
dc.date.accessioned2026-02-03T11:53:39Z
dc.date.available2026-02-03T11:53:39Z
dc.date.issued2026
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractCardiovascular diseases (CVD) are one of the leading causes of death worldwide. Genetic factors, and various environmental factors, including nutrition and the composition of the gut microbiota, have been identified as important factors in the initiation of CVD. Among them, the pivotal role of the gut microbiota in modulating cholesterol metabolism and influencing cardiovascular outcomes has recently been highlighted. Extensive research has confirmed that the gut microbiota has direct and indirect regulatory effects on host cholesterol homeostasis. Recent studies have shown that the microbiota can influence blood cholesterol levels and thus the risk of CVD through various pathways, such as the production of certain metabolites such as bile acids (BAs), SCFAs, and TMAO, the activation of nuclear and membrane-bound receptors such as farnesoid X receptor (FXR), the regulation of gene expression involved in lipid metabolism and inflammatory responses, as well as microbial enzymatic pathways. These complex regulatory mechanisms make the gut microbiota a potential therapeutic target in cholesterol-related diseases and CVD. Microbiota-modulating strategies, including the use of probiotics, prebiotics, fecal microbiota transplantation (FMT), and selective antibiotics, have shown beneficial effects in previous studies. In this regard, in this study, we conducted an in-depth investigation of the regulatory effect of intestinal microbiota on cholesterol metabolism and their impact on the development and progression of atherosclerosis and CVD, and described potential therapeutic pathways based on the regulation of intestinal microbiota in CVD. © The Author(s) 2025.
dc.identifier.doi10.1186/s12986-025-01051-7
dc.identifier.issn1743-7075
dc.identifier.issue1
dc.identifier.scopus2-s2.0-105026962617
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12986-025-01051-7
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34278
dc.identifier.volume23
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.relation.ispartofNutrition and Metabolism
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260130
dc.subjectAtherosclerosis
dc.subjectCholesterol
dc.subjectGastrointestinal microbiome
dc.subjectHomeostasis
dc.titleGut microbiota–cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation
dc.typeReview

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu